Acrivon updates corporate presentation at JPM; confirms cash runway into H2 2025

Acrivon Therapeutics, Inc.

Participates in 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024.
Updated corporate presentation includes product candidate development progress.
Confirms projected cash runway into the second half of 2025.

item 7.01 item 9.01

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-003885

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.